KOSPIBiotech & Pharma137310

SD Biosensor

₩7,210▼ 1.90%2026-11-18 close
Market Cap
₩870.6B
Turnover
₩1.1B
Volume
150K
Shares out.
120M
PER
—
PBR
0.4×
EPS
-₩6,943
Dividend Yield
2.81%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩200 per share · Prices as of the 2026-11-18 close

01

Report overview

Quarterly Operating Profit Turns Positive; Net Income Recovery Is the Test

SD Biosensor returned to a quarterly operating profit of KRW 4.69 billion in Q3 2026, but cumulative net losses attributable to controlling shareholders over the last four quarters still total KRW 831 billion.

  1. 1

    Q3 2026 operating profit of KRW 4.69 billion turned the quarter positive, which the company described as its first quarterly operating profit in four years.

  2. 2

    Revenue reached KRW 710.6 billion in 2025 and has risen for two straight years since 2024, yet the company posted an operating loss of KRW 80.9 billion, extending a three-year run of losses.

  3. 3

    Net losses attributable to controlling shareholders over the last four quarters total KRW 831 billion, with the Q4 2025 loss of KRW 758.9 billion the largest single quarter.

  4. 4

    Cumulative Q3 2026 sales of STANDARD Q reached KRW 86.6 billion, up 21.3% year on year, reflecting the expansion of non-COVID diagnostic products.

  5. 5

    In an October 2026 disclosure of its corporate value-up plan, the company set a target of a price-to-book ratio of 1.0 times or higher by 2029.

02

Business structure

SD Biosensor is a global in-vitro diagnostics company that tests blood and other specimens outside the body to identify disease. Its core lines are the rapid test kit STANDARD Q, the M10 series of immunoassay products, and the fluorescence immunoassay brand STANDARD F.

Cumulative Q3 2026 sales of STANDARD Q reached KRW 86.6 billion, up 21.3% year on year, with sales to Africa rising mainly for malaria and sexually transmitted infection tests.

Its sales model relies heavily on overseas subsidiaries, and according to company figures, first-half 2026 sales at the Indian subsidiary reached KRW 45.9 billion, up 31% year on year.

Growth at the Indian unit was supported by higher procurement volumes from the WHO, while the Spanish subsidiary's Q1 2026 sales rose 313% year on year, the company said. First-half 2026 sales at the headquarters rose 9.4% year on year to KRW 152.6 billion.

Key customers include international bodies such as the WHO and the Global Fund, as well as government procurement channels, and the tuberculosis test M10 MTB-RIF/INH has been listed on the Global Fund procurement list.

In 2023 the company acquired the US diagnostics firm Meridian Bioscience, broadening its footprint in the US market. According to the company, non-cash amortization of intangible assets from that deal continues to weigh on operating results, and the company said adjusted operating results excluding it are in the black. Competition centers on product approvals (CE-IVDR, FDA, WHO PQ) and international procurement systems.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩164.2B-₩14B−8.5%
2025Q4₩194.6B-₩31.8B−16.4%
2026Q1₩193.5B-₩11.6B−6.0%
2026Q2₩186.5B-₩7.3B−3.9%
2026Q3₩188.6B₩4.7B2.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩2.9T₩1.1T₩911.4B39.1%31.0%10.7%
2023₩655.7B-₩248.1B-₩467.7B−37.8%−16.6%33.8%
2024₩694.6B-₩54.1B-₩98.4B−7.8%−3.4%32.6%
2025₩710.6B-₩80.9B-₩512.1B−11.4%−22.0%38.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual results show revenue dropping sharply in 2023 from the 2022 peak, followed by a recovery in sales since 2024 while losses persisted.

Revenue fell from KRW 2.93 trillion in 2022 to KRW 655.7 billion in 2023, a decline of 77.6% year on year, then rose to KRW 694.6 billion in 2024 (up 5.9%) and KRW 710.6 billion in 2025 (up 2.3%), marking two consecutive years of growth from 2024 through 2025. 2022 was the largest year in the period and 2023 the smallest.

Operating profit went from KRW 1.15 trillion in 2022 to an operating loss of KRW 248.1 billion in 2023, a swing into deficit; the loss narrowed to KRW 54.1 billion in 2024 and widened to KRW 80.9 billion in 2025, a three-year run of operating losses from 2023 through 2025.

The operating margin moved from 39.1% in 2022 to -37.8% in 2023, -7.8% in 2024 and -11.4% in 2025, so the loss ratio widened in 2025 even as revenue grew.

Net income attributable to controlling shareholders swung from KRW 911.4 billion in 2022 to a net loss of KRW 467.7 billion in 2023, then a net loss of KRW 98.4 billion in 2024 and KRW 512.1 billion in 2025.

Net income including non-controlling interests, reported separately, was a net loss of KRW 513.4 billion in 2025. Operating cash flow went from -KRW 242.3 billion in 2023 to KRW 156.5 billion in 2024 and KRW 357.5 billion in 2025, turning positive.

On a quarterly basis, revenue rose from KRW 164.2 billion in Q3 2025 to KRW 194.6 billion in Q4 2025 (up 18.5% quarter on quarter), then KRW 193.5 billion in Q1 2026, KRW 186.5 billion in Q2 2026 and KRW 188.6 billion in Q3 2026 (up 14.9% year on year).

Operating results went from an operating loss of KRW 14 billion in Q3 2025 and KRW 31.8 billion in Q4 2025 to losses of KRW 11.6 billion in Q1 2026 and KRW 7.3 billion in Q2 2026, and then an operating profit of KRW 4.69 billion in Q3 2026.

Among the last five quarters, the Q4 2025 net loss attributable to controlling shareholders of KRW 758.9 billion is the largest, and after net profits of KRW 22.7 billion in Q1 2026 and KRW 16.5 billion in Q2 2026, Q3 2026 posted a net loss of KRW 111.2 billion, with the loss widening year on year.

The company said cumulative operating losses for the first nine months of 2026 were KRW 14.2 billion, down about 71% year on year, and that the cumulative net loss reflects foreign currency translation losses on dollar assets as the won-dollar rate fell.

05

Industry analysis

The in-vitro diagnostics market is being reshaped toward non-COVID products after demand for COVID-19 tests faded in the endemic period. The 77.6% sales drop in 2023 reflected a fall in diagnostic kit sales along with inventory-related losses, showing how strongly sector shifts can move reported results.

The company says it is shifting its product focus toward malaria, sexually transmitted infections, tuberculosis, respiratory and chronic disease tests. Demand for these products comes largely from international bodies and government procurement, so quarterly sales tend to move with procurement timing.

The company has repeatedly attributed overseas subsidiary sales gains to higher procurement volumes. Management says demand for non-COVID tests is expanding in emerging markets and in Europe.

On regulation, approvals such as CE-IVDR in Europe, FDA in the US and WHO PQ for international procurement set the terms of market access. In terms of position, the company operates local subsidiaries across Europe, India, Indonesia, Panama and Spain.

It entered the US market through the Meridian acquisition, and amortization burdens from that deal still weigh on reported results. How far the expansion of non-COVID products restores sales scale is the central variable for judging the sector outlook.

06

Outlook

In its first-half 2026 results announcement in August, the company said it would pursue a medium- to long-term growth strategy built on its total diagnostics platform.

In May 2026 it said it would strengthen regional platform businesses and pursue sales growth and margin improvement based on global approvals including CE-IVDR, FDA and WHO PQ.

In its corporate value-up plan disclosed on October 22, 2026, the company set a target of a price-to-book ratio of 1.0 times or higher by 2029, with an interim target of 0.65 times or higher for 2027.

Its shareholder return plan covers 2026 through 2028, using at least 20% of standalone operating profit for cash dividends and retiring one million treasury shares each year. The company also said it would actively pursue an interim dividend if results improve.

On the financial side, repayment of exchangeable bonds and external borrowings reduced interest expense, and according to company figures the debt-to-equity ratio stood at 20.6% at the end of the first half of 2026.

On the business side, sales growth of the tuberculosis tests M10 MTB-RIF/INH and M10 MTB/NTM is a positive factor, and the former has been listed on the Global Fund procurement list.

The variables to watch are whether the Q3 2026 operating profit continues into Q4, and how the large Q4 2025 net loss is explained in the 2026 annual report. The timing of procurement volumes at overseas subsidiaries will also shape the quarterly sales path.

07

Valuation

PER
—
PBR
0.4×
ROE
-31.8%
EPS
-₩6,943
BPS
₩18,137
Dividend per share
₩200

Because net losses attributable to controlling shareholders have continued over the last four quarters, the price-to-earnings ratio cannot be calculated. By contrast, the price-to-book ratio is well below 1 times, so the share price sits below book value per share, a factual comparison that can be stated.

The company's October 2026 disclosure set a target of a price-to-book ratio of 1.0 times or higher by 2029, which provides a reference point for measuring the distance from the current multiple.

On dividends, the policy specifies that at least 20% of standalone operating profit will fund cash dividends for 2026 through 2028, so the actual payout depends on operating performance.

The move from quarterly losses to profits in the past loss period shows the direction of earnings recovery, but whether net profit attributable to controlling shareholders has stabilized is so far confirmed only in two quarters, Q1 and Q2 2026.

The debt-to-equity ratio moved lower, from 38.8% at the end of 2025 to 20.6% at the end of the first half of 2026 according to company figures, reducing financial burden. Valuation multiples for this stock are best read alongside the path of earnings recovery.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Quarterly operating profit turns positive

Q3 2026 operating profit of KRW 4.69 billion turned the quarter positive. The company described it as the first quarterly consolidated operating profit in four years. Cumulative operating losses for the first nine months of 2026 narrowed to KRW 14.2 billion, down about 71% year on year. The company says results excluding amortization charges remain in the black.

Growth in non-COVID products

Cumulative Q3 2026 sales of STANDARD Q rose 21.3% year on year to KRW 86.6 billion. Malaria and sexually transmitted infection tests, along with sales to Africa, drove the growth. First-half sales at the Indian subsidiary rose 31% year on year. Growth in overseas subsidiary sales widens the revenue base beyond the headquarters.

Balance sheet repair and shareholder returns

The company said repayment of exchangeable bonds and external borrowings reduced interest costs. First-half 2026 interest expense fell about KRW 17.7 billion year on year. Its October 2026 plan includes cash dividends funded from 2026 through 2028 and the retirement of one million treasury shares each year. The company also highlighted an employee share purchase as a sign of management accountability.

09

Bear factors

Persistent net losses for controlling shareholders

Net losses attributable to controlling shareholders over the last four quarters total KRW 831 billion. The Q4 2025 loss of KRW 758.9 billion accounts for most of that total.

Q3 2026 posted a net loss of KRW 111.2 billion attributable to controlling shareholders despite the operating profit, and the loss widened year on year. The company cited foreign currency translation losses as a factor behind the cumulative net loss.

Acquisition amortization and annual losses

The operating loss for 2025 was KRW 80.9 billion, extending a three-year run of losses from 2023. The operating margin was -11.4% in 2025, lower than -7.8% in 2024. According to the company, non-cash amortization of intangible assets linked to the Meridian acquisition continues to be reflected in operating results. The gap between adjusted profitability and reported results remains a bearish factor.

Volatile sales recovery

Revenue fell from KRW 2.93 trillion in 2022 to KRW 710.6 billion in 2025, and the recovery remains at an early stage. Quarterly sales declined in Q1 and Q2 2026 before edging up in Q3. Because quarterly revenue moves with international and government procurement volumes, reported results are prone to volatility. The pace of non-COVID sales may remain uneven if it depends on procurement timing.

10

Risk factors

Currency and foreign-asset valuation

A decline in the won-dollar rate can generate foreign currency translation losses on dollar assets, weighing on net income. The company cited this factor for the cumulative net loss in the first nine months of 2026. Currency swings can move net income independently of operating trends. Net results may therefore diverge from operating profit even if operating profitability continues.

Approvals and procurement policy

Approval timelines under CE-IVDR, FDA and WHO PQ, along with international and government procurement policy, are variables the company cannot fully control. If procurement volumes shrink or timing slips, overseas subsidiary sales could swing from quarter to quarter. Because the product mix is shifting toward non-COVID tests, the pace of margin improvement is uncertain.

Financial position and amortization burden

Total liabilities at the end of 2025 were KRW 905.9 billion and total equity KRW 2.34 trillion. Debt repayment has eased the burden, but amortization of intangible assets continues to sit in operating results. Larger impairments or amortization could slow the pace of net income recovery. Even with a lower debt ratio, continued losses would erode capital depending on their size.

11

What to watch next

  1. Early 2027

    Preliminary Q4 2026 results. This is the checkpoint for whether the operating profit trend held through the full year 2026 and whether net income attributable to controlling shareholders stabilized after the large Q4 2025 loss.

  2. End of March 2027

    Filing of the 2026 annual report. Alongside the full-year operating margin, net income attributable to controlling shareholders and operating cash flow, it shows whether the 2026 to 2028 cash dividends and treasury share retirements were carried out.

  3. Around mid-August 2027

    First-half 2027 results. This is where to check whether operating profit and net income attributable to controlling shareholders hold at first-half 2026 levels and whether lower interest expense continues to support results.

12

Overall view

SD Biosensor's revenue fell sharply in 2023 after its 2022 peak and then rose in both 2024 and 2025, but operating losses have persisted for three straight years from 2023. Quarterly results shifted in 2026.

Net income attributable to controlling shareholders was positive in Q1 and Q2, and Q3 returned to a quarterly operating profit of KRW 4.69 billion. However, the same quarter posted a net loss of KRW 111.2 billion attributable to controlling shareholders, bringing the four-quarter cumulative loss to KRW 831 billion.

The company attributed the cumulative net loss to foreign currency translation losses from the weaker won against the dollar. On the financial side, debt repayment cut the debt-to-equity ratio from 38.8% at the end of 2025 to 20.6% at the end of the first half of 2026, according to company figures.

The 2029 price-to-book target of 1.0 times or higher and the shareholder return plan show the direction of the corporate value-up effort, while the distance between the current multiple and that target will depend on how quickly earnings recover.

The bullish factors are the return to operating profit and growth in non-COVID products, while the bearish factors are persistent net losses and amortization burdens. The next checkpoints are the Q4 2026 preliminary results and the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. wowtv.co.kr
  2. wowtv.co.kr
  3. m.news.nate.com
  4. getnews.co.kr
  5. m.news.nate.com
  6. m.news.nate.com
  7. edaily.co.kr
  8. vegannews.co.kr
  9. m.news.nate.com
  10. thebionews.net
  11. m.thinkpool.com
  12. markets.hankyung.com
  13. m.thinkpool.com
  14. news1.kr
  15. datatooza.com
  16. businesspost.co.kr
  17. judal.co.kr
  18. judal.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis